U.S. guideline nixes prostate screening in under-55s Late toxicities of cancer drugsCardiac, pulmonary, sexual, and neurologic toxicities that develop or persist after completing cancer drug therapy New U.S. guideline nixes prostate cancer screening in under-55s Two-year interval suggested for older men who opt for testing Robot fails to impress in bladder cancer surgery High-tech approach no better than conventional open procedure Prostate cancer: More men can opt for active surveillance Not all conventional criteria need to be fulfilled, analysis shows New Drug: Perjeta for the treatment of HER2-positive metastatic breast cancer New drug is a recombinant, humanized, monoclonal antibody. Implants a cancer hazard Intermittent versus continuous prostate cancer therapy: New trial raises cautions in metastatic disease Researchers unable to conclude the two strategies produce equivalent results Made-in-Canada technology aims to zap early prostate cancer Safety trial of MRI-guided ultrasound ablation launched in Ontario MRI an option for colon screening? Technique has the advantage of avoiding radiation exposure First Previous 36 37 38 39 40 Next Last